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Endometrial carcinoma is one of the most common gynaecological
malignancies. Despite the high morbidity associated with this
neoplasia, little is known about its underlying genetic mecha-
nisms. However, recent investigations have documented the
involvement of a few oncogenes and tumour suppressor genes in
endometrial carcinoma. Among them a high incidence of allelic
loss has been noted for chromosome 18q in this tumour (Imamura
et al, 1992). The region within or near the chromosome region
18q21, which is involved in deletions in endometrial cancers,
contains the DCC gene. Loss of appropriate transcription in most
endometrial carcinoma cell lines and surgically resected tumours
(Gima et al, 1994; Enomoto et al, 1995; Ronnett et al, 1997) is
compatible with the assumption that inactivation of the DCC gene
has a role in endometrial carcinoma development. Similarly,
significant incidence of loss of heterozygosity (LOH) on chromo-
some 18q and decreased or absent expression of the DCC gene
comparing with the normal counterparts were revealed in a variety
of other human malignancies of epithelial origin as well as gastric,
pancreatic, breast and prostate cancers (Devileei et al, 1991;
Neuman et al, 1991; Hoene et al, 1992; Gao et al, 1993; Miyake et
al, 1993; Scheek et al, 1993; Brewster et al, 1994). However, there
is little proof to categorize DCC directly as a tumour suppressor
gene. Localized somatic mutations predicted to inactivate the
remaining DCC allele have been identified only in a fraction of
colorectal cancers (Cho et al, 1994). The length and complexity of
the DCC gene restrict the demonstration of DCC involvement in
various malignancies including endometrial carcinomas. A single
chromosome 18 transfer into endometrial carcinoma cells has been
shown to suppress tumorigenicity, whereas growth properties in
vitro were not significantly affected (Yamada et al, 1995).
However, it remains unknown whether the suppression of tumour
formation was due to DCC expression or to expression of some
other genes on the transferred chromosome. The recent data define
a minimally lost region on chromosome 18q21 in a few carci-
nomas, which contains at least two candidate tumour suppressor
genes, DPC4 and DCC (Thiagtlingam et al, 1996). The deletion
analysis further suggested genetic heterogeneity in colorectal
carcinomas, with DPC4 the deletion target of chromosome 18q21
in up to a third of the cases, and DCC or neighbouring gene the
target in the remaining tumours. However, retained alleles of
DPC4 are mutated in only a fraction of colorectal cancers that
suffers 18q LOH (Kei et al, 1996; Takagi et al, 1996).
DCC encodes for a membrane-bound protein with immuno-
globulin like and fibronectin type III domains and a unique cyto-
plasmic domain (Fearon et al, 1990). The first two domains are
characteristic of an adhesion molecule belonging to the
immunoglobulin superfamily, the members of which are expressed
mainly on cells of the nervous and immune systems. These struc-
tures of DCC provide the possibility that DCC associates with cell
differentiation as an adhesion molecule. Localization of DCC
protein in a subset of differentiated cells would support this
(Hedrick et al, 1994). Recently, DCC protein was found to be a
Netrin-1 receptor in neural cells (Keino-Masu et al, 1996). Netrin-
1 is related to the extracellular matrix protein laminin and secreted
by floorplate cells as a chemoattractant for commissural axons in
the vertebrate spinal cord (Kennedy et al, 1994). Netrin-1 or DCC-
deficient transgenic mice showed the identical phenotype, which
exhibits the defects in spinal commissural axon projections and in
brain morphogenesis (Serafini et al, 1996; Fazel et al, 1997). Thus,
Netrin-1–DCC signalling plays a crucial role in nervous system
development. Although there are few data to define the role of
DCC in non-neural cells, Mehlen et al (1998) found that DCC,
which was a caspase substrate, could induce apoptosis in the
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The data suggest that DCC functions as a tumour suppressor
protein by inducing apoptosis in settings in which ligand is
unavailable. Klingelhutz et al (1995) also demonstrated a direct
role of DCC in tumour suppression of nitrosomethylurea-trans-
formed tumorigenic human papillomavirus (HPV)-immortalized
human epithelial cells (1811-NMU-T1 cells). This observation
supports the function of DCC as a tumour suppressor. However,
DCC-deficient transgenic mice showed no increased incidence of
colorectal cancers (Fazel et al, 1997). Therefore, the role of DCC
in suppression of the malignant phenotype still remains to be
elucidated.
Reconstituted DCC expression in the DCC-negative carcinoma
cells is able to provide a clue to its functions. In the present study,
we investigated the expression levels of DCC protein in human
endometrium to define the association with altered DCC expression
and endometrial carcinoma development. Then, we examined the
effect of reconstitution of DCC expression on the malignant pheno-
types exhibited by endometrial carcinoma cells. Reconstituted
levels of DCC protein in the DCC-non-expressing carcinoma cells
Ishikawa were almost analogous to the level detected physiologi-
cally in human endometrium. We now show here that the wild-type
full-length DCC cDNA can inhibit both in vitro growth and tumori-
genicity in Ishikawa endometrial carcinoma cells, and can inhibit
tumorigenicity in HHUA endometrial carcinoma cells. A potential
of DCC to induce apoptotic cell death at least partly contributes to
the inhibitory effects. Moreover, tumorigenic revertants originated
from the non-tumorigenic transfectants abrogate the exogenous
DCC cDNA expression.
MATERIALS AND METHODS
Cell lines and plasmid transfection
Endometrial carcinoma cell lines (HHUA and Ishikawa) were prop-
agated in high glucose Dulbecco’s Modified Eagle’s medium
(Gibco-BRL-Life Technologies) supplemented with 10% fetal
bovine serum (FBS; Medical Link, Yokohama, Japan). All cell lines
were negative for the presence of Mycoplasma. HHUA and
Ishikawa cells expressing full-length DCC were obtained by trans-
fection with the mammalian expression vector pDCCCMV-S. The
cells were transfected with a mixture of 5 mg plasmid DNA and
cationic liposomes [Lipofectin reagent (Gibco-BRL-Life
Technologies)]. Approximately 48 h after transfection, selection in
G418 at 600 mg ml–1 was started. Single G418-resistant clones were
trypsinized and established as clonal cell lines. The cell lines were
maintained in G418 at 400 mg ml–1.
RT-PCR analysis of DCC gene expression
Total RNA was prepared from the cell lines, clones and surgically-
removed normal human uterine endometrium using the acid guani-
dinium thiocyanate method (Chomoczynski et al, 1987). Three
micrograms of the total RNAs were reverse transcribed (RT) into
first-strand cDNA with random hexamer and the Gene Amp, RNA
polymerase chain reaction (PCR) core kit (Perkin-Elmer, NJ, USA).
The cDNA was then amplified by PCR using primer pairs derived
from the transfected DCC cDNA sequence. Four sets of primers
covering the whole sequence of DCC were used to analyse the expres-
sion. Primer 1 for exons 1–7, sense; 5¢-ATGGAGAATAGTCTTA-
GATG-3 antisense; 5¢-CAATGAGCTGTGCACTGGAC-3, primer 2
for exons 7–16, sense; 5¢-ATGAGGCTGGAAATGCCCAG-3¢ anti-
sense; 5¢-ATAGACCTGGTGGTGGCACT-3¢, primer 3 for exons
16–24 sense; 5¢-TGCCGGAGAAGGAGTTCCTC-3¢, antisense; 5¢-
GCTTCCCAGTTGGGTTTCTG-3¢ and primer 4 for exons 24–29,
sense; 5¢-ACCAGTCAGCCACAGCCAGT-3 antisense; 5¢-CTTG-
GACAGGTGTGCTGT-3 were synthesized for the inter-exon PCR.
PCR condition included denaturation for 1 min at 94°C, annealing for
1 min at 56–60°C and extension for 2 min at 72°C. RT-PCR products
were electrophoresed on 1.2% agarose gels and transferred to Nylon
membrane (Hybond-N+, Amersham). Their identities were con-
firmed by hybridization with a 32P-labelled DCC cDNA probe puri-
fied from pDCCCMV-S.
Immunohistochemical and Western blot analyses of
DCC expression
Surgically-resected normal human endometrium was fixed in 10%
formalin and sections were made onto glass slides. These slides
were reacted with antibodies recognizing intracellular DCC
domain or extracellular domain (15041A and 15031 respectively;
Pharmingen, San Diego, CA, USA), according to the manufac-
turer’s recommendations. After the incubation of the primary anti-
body, signals were detected with the anti-mouse biotin-labelled
antibody following the treatment with avidin-peroxidase and
DAB.
Cell lines or tissue homogenates were solubulized in Tris-
buffered saline (25 mM Tris (hydroxymethylaminomethane),
pH 8) with detergents (1% Nonidet P-40, and 0.1% sodium
dodecyl sulphate (SDS)) and protease inhibitors (5 mg ml–1 apro-
tinin, 2 mg ml–1 leupeptin, 100 mg ml–1 phenylmethylsulphonyl
fluoride, and 1 mM EDTA). Protein concentrations were then
determined. Unprocessed cell line/tissue lysates underwent SDS
polyacrylamide gel electropheresis (SDS-PAGE) (100 mg per
lane) and transblot semi-dry transfer (Bio-Rad, Hercules, CA,
USA) to nitrocellulose membranes (Schleicher and Schuell,
Germany). The primary DCC antibody (Ab-1) (Oncogene
Science, NY, USA) was used at 1 mg ml–1, and the secondary
goat–anti-mouse antisera coupled to horseradish peroxidase
(Amersham) was used at a 1:10 000 dilution. The antigen–-
antibody complex was detected by enhanced chemiluminescence
(ECL; Amersham) and subsequent exposure to Hyperfilm
(Amersham).
Evaluation of in vitro transformed phenotype and
tumorigenicity
The greatest cell number after reaching confluency was counted to
calculate the saturation density. For the evaluation of anchorage
independent growth, a single cell suspension (103) of parents and
clones in 0.3% agar were overlaid on 0.5% basal agar. Colony-
forming efficiencies, based on colonies with a diameter of
> 0.2 mm, were scored after 4 weeks’ observation. To evaluate
tumorigenicity in vivo, 5 ´ 106 cells in 0.2 ml of serum-free media
were inoculated subcutaneously into 5- to 9-week-old athymic
Balb 3T3 nu/nu mice. Animals were observed regularly every
week up to 12 weeks. Tumour-take incidence and the period
required for a tumour to gain the volume of 4180 mm3 were deter-
mined. The volume was calculated with the dimensions by consid-
ering a tumour as an ellipse.
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High molecular weight DNA was extracted from the cells, by the
incubation with 0.5% SDS and 50 mg ml–1 proteinase K following
the phenol–chlorform extraction. Three micrograms of DNA were
electrophoresed in 1.8% agarose gel and stained with ethidium
bromide for the observation of ladder formation.
Nucleosome sized DNA fragmentations by apoptosis was also
observed by TUNEL assay (Clifton et al, 1998), using Apop Tag
(Intergen Co., Oxford, UK) following the manufacturer’s instruc-
tions. The ratio of positive staining was determined by counting
the average of positive nuclei per 100 cells in three independent
microscopic fields.
RESULTS
Abundant expression of DCC protein in normal human
endometrium
First of all, we examined the expression of DCC protein and
mRNAs in six human endometrial tissue samples. Immunohisto-
chemical analyses showed the positive staining in normal human
endometrium, that was consistent with membrane localization of
endometrial gland cells. We used two antibodies, which recognized
extracellular (15031A) and intracellular domains (15401A) (Figure
1). Both antibodies showed a similar staining pattern. In turn, we
failed to detect positive signals in seven out of twelve endometrial
cancer samples (Figure 1), being consistent with our previous
observation that half of 28 surgically resected tumours lost DCC
gene expression (Gima et al, 1994). Immunoblot studies revealed a
definite signal band that was an apparent molecular weight
190 kDa in normal human endometrial tissues (Figure 2A). To
characterize the DCC protein expressed in human endometrium,
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Figure 1 Immunohistochemical detection of DCC protein in human
endometrial glands. Positive staining was observed in human endometrial
gland epithelium by anti-DCC antibodies which recognize intracellular (A)
and extracellular domain (B). In contrast, interstitial cells outside the glands
in the same photograph and one representative cancer specimens (by
antibodies which recognize intracellular domain (C)) had no signal. Though
all the samples are not shown in this figure, seven out of 12 cancer












Figure 2 (A) Immunoblot detection of DCC protein in normal endometrium
and Ishikawa endometrial carcinoma clones. One hundred mg of protein per
lane was analysed by SDS-PAGE and followed by ECL detection with anti-
DCC monoclonal antibody Ab-1. Parental Ishikawa, 1; Ishikawa transfected
with control plasmid pCMVneo, 2; DCC cDNA transfected Ishikawa clone 55,
3; clone 519, 4; clone 528, 5; independent normal endometrial tissue
samples, 6–8. The 190 kDa band in Ishikawa clones and the 175 kDa band
in the normal endometrium were detected. (B) RT-PCR of RNAs from normal
endometrium for DCC coding region. PCR of pDCCCMV-S (1), and RT-PCR
of RNAs from clone 55 (2) and normal endometrium (3). Primer sets 1 (P1)
covers nt 1 to 1248. Similarly, P2 covers nt 1220 to 2450, P3 covers 
nt 2403 to 3600 and P4 covers nt 3560 to 4468 respectively. Arrows indicate
corresponding PCR products. All the products amplified with the same primer
sets showed identical sizean RT-PCR-based approach was used to determine whether the 175
kDa protein resulted from alternative splicing or post translational
modification. By using four sets of primers designed for the full-
length ORF, PCR amplification of cDNAs obtained from human
endometrium produced products that were identical to the size
predicted for the DCC cDNA sequences (Figure 2B). Sequencing
of the products showed that human endometrium expressed DCC
transcript encoded from the full-length ORF.
We investigated the expression of the DCC ligand, netrin-1 in
normal human endometrial tissues (both proliferative and secretory
phases) and the human endometrial cancer cell lines, HHUA and
Ishikawa. Based on the sequence data (NCBI, Entrez Nucleotide
Query; http://HYPERLWK; http://www.ncbi.nlm.nih.gov), we
designed two primer sets to amplify netrin-1 cDNAs (190–1060 nt and
1021–1800 nt respectively). However, no amplification was observed
in normal human endometrium and two endometrial cancer cell lines.
Isolation of endometrial cancer cell clones expressing
exogenous DCC
To obtain functional evidence for DCC as a tumour suppressor
gene associated with endometrial cancer development, we trans-
fected human endometrial carcinoma cells with the human DCC
cDNA encoding a complete ORF (Hedrick et al, 1994). The
human endometrial cancer cell lines, HHUA and Ishikawa,
showed highly transformed growth properties and were tumori-
genic in nude mice (Oshimura et al, 1990). A previous report
demonstrated the absence of DCC expression in these cells by
using RT-PCR analyses (Gima et al, 1994). The plasmid con-
taining full-length DCC cDNA between CMVLTR and rabbit b-
globin poly A signal (generous gift from M Sherman and B
Vogelstein) was used for the transfection (pDCCCMV-S) (Hedrick
et al, 1994). The ORF of DCC cDNA obtained from human brain
predicts a protein of approximately 153 000 molecular weight.
The pCMVneo that was the vector without the cDNA was also
used for the transfection experiment as a control. pDCCCMV-S
and pCMVneo were introduced into the two endometrial cancer
cell lines with cationic liposome.
Selected HHUA clones were examined for the restored DCC
expression. Western blots using protein extracted from parental
HHUA cells and pCMVneo transfectants revealed no signal with
anti-DCC monoclonal antibody Ab-1. We also assessed 12 clones
obtained from pDCCCMV-S transfectants and failed to detect
DCC protein expression in any of these clones. However,
hybridization of RT-PCR products with a probe corresponding to
DCC cDNA produced an apparent signal in these 12 clones but not
in the parental cells or pCMVneo clones (Figure 3). We previously
determined that the RT-PCR method detected transcription of 1/10
copy of DCC per cell and this could not detect DCC transcription
in the parental HHUA cell (Gima et al, 1994). Thus, the restored
transcription in pDCCCMV-S transfectants resulted from the
expression of exogeneously introduced DCC cDNA. The relative
insensitivity of Western blot analyses may account for the failure
to detect DCC protein expressed in the pDCCCMV-S transfec-
tants.
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Figure 3 Transfected DCC transcripts detected by RT-PCR in HHUA
clones. RT-PCR with different source of RNA was done by the set of primer
(primer 1) spanning nt 1–1249 of DCC cDNA coding region. PCR products
were electrophoresed in 1.2% of agarose gel and subjected to hybridization
with 32P-labelled DCC cDNA probe. Parental HHUA, P; HHUA transfected
with control plasmid pCMVneo, C; DCC CDNA transfectant clone 7, 1; clone
9, 2; tumours from clone 7, 3–6; tumours from clone 9, 7; clone 11, 8; PCR
products with RNA samples without using reverse transcriptase from clone 7,
R1; clone 9, R2; clone 11, R3. Only the original pDCCCMV-S transfected
clones showed the positive signal, but the tumours generated from the
clones did not show the signal. The same results were obtained with other
primer pairs (primer 2–4) (data not shown). Amplification of GAPDH of
corresponding RNA was also shown below as qualitative control
Table 1 Growth properties of DCC transfected clones
Generation Saturation density Tumorigenicity in nude mice DCC expression
Clone time (h) (´ 105 cm–2) AIG (%) (latency)a RT-PCR WB
HHUA 43.7 6.7 11.6 5/5 (53.4) – –
CT 59.0 6.8 11.0 7/8 (58.1) – –
CL7 49.2 3.9 12.0 4/8 (68.7) + –
CL9 41.7 4.0 10.2 1/6 (119.0) + –
CL11 79.1 4.4 13.0 0/7 + –
Ishikawa 25.7 3.4 8.7 4/4 (72.3) – –
CT 33.4 3.0 6.8 4/4 (89.7) – –
CL55 32.9 2.7 0.3 0/4 + +
CL519 (166.3)b 1.2 0 0/4 + +
CL528 (305.6)b 0.7 0 ND + +
aDays for tumour to 4180 mm3. bAfter a month of culture. ND: not determined.In contrast to HHUA cells, pDCCCMV-S transfection resulted
in the appearance of clones expressing a 175 kDa protein detected
with anti-DCC Ab-1 monoclonal antibody in Ishikawa cells
(Figure 2A). The expression levels in these clones were roughly
comparable to that in six human endometrial tissue samples.
However, the parental Ishikawa cells and pCMV transfectants
failed to express detectable proteins. These results were confirmed
by RT-PCR and Southern blots in which highly abundant RT-PCR
products were detected in all clones from the pDCCCMV-S trans-
fectants, but the product was absent in the parent and its pCMVneo
transfectants. The protein size detected in the pDCCCMV-S trans-
fectants derived from Ishikawa cells was smaller than the one
expressed in normal endometrium. As described previously, the
apparent difference in molecular mass is likely attributable to post-
translational modification, perhaps by glycosylation at potential
N-linked glycosylation sites in the extracellular domain (Reale et
al, 1994). Each of three representative clones from the HHUA- and
Ishikawa-derived pDCCCMV-S transfectants were chosen for
further analyses.
Exogenously introduced DCC suppresses transformed
cell properties in endometrial carcinoma cells
DCC expression significantly reduced the saturation density in
HHUA cells; a 60–70% reduction was detected in pDCCCMV-S
transfectants, compared to those in parent or pCMVneo transfec-
tants (Table 1). However, there were no consistent morphological
alternations in pDCCCMV-S transfectants of HHUA grown in
monolayer cultures. In addition, expression of exogenously intro-
duced DCC in HHUA cells did not affect in vitro cell growth rate
or growth in soft agar cultures with exception of one of three
pDCCCMV-S transfectants (clone 11); this showed prolonged
population doubling. These findings sharply contrasted to the
suppression of in vitro growth properties in Ishikawa cells.
Expression of exogenous DCC resulted in a prominent prolonga-
tion of population doubling and reduction in saturation density in
Ishikawa cells, which were not observed in pCMVneo transfec-
tants. Soft-agar cultures of pDCCCMV-S transfectants of Ishikawa
also produced no colonies.
Expression of exogenously introduced DCC in Ishikawa cells
resulted in alterations in cell morphology and adhesiveness to the
plates (Figure 4). The cells were smaller in size and round in
shape. The nuclei were condensed and fragmented (data not
shown) in the majority of cells that detached from the plates. When
high molecular weight DNAs were extracted from pDCCCMV-S
transfectants derived from Ishikawa cells and electrophoresed in
2.0% agarose gel, DNA ladders compatible with apoptotic cell
death were observed. DNA fragmentation was seen in all clones
from Ishikawa derived pDCCCMV-S transfectants (Figure 5).
However, no DNA ladder formation was observed in parent
Ishikawa cells, their pCMVneo transfectants or HHUA-derived
pDCCCMV-S transfectants. In addition, the apoptotic cell death
was also evaluated by using TUNEL assay. Positive signals in
nuclei, which indicated apoptotic cell death, was observed in 20%
of cells in clone 55, 64% of cells in clone 519 and 22% of cells in
clone 528, being contrasted with 6% of parental Ishikawa cells.
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Figure 4 Morphology of parental Ishikawa cells (A) and their pDCCCMV-S
transfectant clone 528 (B). Most of the clone 528 cells showed the round
shape and smaller size, and easily detached from plate surface.
Magnification was 1003
23 14 M
Figure 5 Apoptotic ladder observed in Ishikawa-derived pDCCCMV-S
transfectant clones. Three micrograms of high molecular weight DNA was
subjected to each lane. After the electrophoresis in 1.8% agarose gel, the gel
was stained by ethidium bromide. Lambda HindIII marker, M; parental
Ishikawa, 1; clone 55, 2; clone 519, 3; clone 528, 4. All Ishikawa-derived
pDCCCMV-S transfectant clones which had the apoptotic morphology showed
the DNA ladders, that was not seen in parental Ishikawa cells (lane 1)These findings suggest that DCC protein expressed in DCC-
deficient Ishikawa endometrial cancer cells induces apoptosis.
However, the level of DCC protein expression in HHUA cells may
have been too low to induce apoptosis or these cells may respond
differently to DCC expression due to other genetic alterations. To
address whether low levels of DCC protein expression would
affect a potential to induce apoptosis, we isolated a single clone
that expressed a reduced level of DCC protein (clone 55-late) and
two clones that failed to express DCC protein (clone 519-late and
clone 528-late) by prolonged passage of the Ishikawa derived
pDCCCMV-S transfectants (Figure 6). RT-PCR-Southern blots
were still able to detect DCC cDNA transcription in these late
passage clones. The cells did not exhibit DNA fragmentation
under condition of either 10% or 0.2% serum. And TUNEL assay
positive cells ranged from 4 to 8% in these late passage clones.
Thus, the level of DCC protein expression may be critical to
induce apoptotic cell death in DCC-deficient endometrial cancer
cells.
To determine if DCC suppressed tumorigenicity, we injected
pDCCCMV-S transfectants subcutaneously into nude mice (Table
1). The parent HHUA and Ishikawa cells, and pCMVneo transfec-
tants gave rise to rapidly growing tumours. After a latency period
of 50–53 days for HHUA and 72–90 days for Ishikawa cells, 20
out of 21 sites injected with either parental cells or their vector
transfectants developed progressively growing tumours. In
contrast, cells with expression of exogenous DCC exhibited a
suppression of tumour incidence and growth. Five tumours devel-
oped from 21 sites in which HHUA-derived pDCCCMV-S trans-
fectants were inoculated. Inoculation of Ishikawa-derived
pDCCCMV-S transfectants at eight sites produced no tumours.
The five tumours produced by the inoculation of HHUA-derived
pDCCCMV-S transfectants grew slightly slower than the ones by
inoculations of the parent or its pCMVneo transfectants. Average
times required to reach 4180 (mm3) in volume ranged from 68 to
119 days. This contrasted with the time for tumours to develop
from the parental cell inoculation (53 days) or the pCMVneo
transfectant inoculation (58 days). The tumours produced by inoc-
ulation of pDCCCMV-S transfectants were poorly differentiated
adenocarcinomas similar to those obtained by inoculations of
parent or its pCMV transfectants. The cells obtained from these
five tumours were examined for DCC mRNA expression,
following the incubation in vitro for a few weeks in the presence of
G418. DCC mRNA was not detectable by the RT-PCR, indicating
deletion or silencing of transfected DCC cDNA sequences (Figure
3).
DISCUSSION
Transfection of DCC cDNA under control of the strong CMV
promoter into two human endometrial carcinoma cells lacking
expression of the endogenous DCC gene produced cells that
expressed different levels of exogenous DCC. The transfected
HHUA cells expressed a very low level of DCC that was unde-
tectable with Western blot analyses. DCC expression had little
effect on in vitro growth of HHUA cells. In contrast, the trans-
fected Ishikawa cells expressed readily detectable levels of DCC
protein, which was similar to the levels detected in normal human
endometrial tissues. Abundant DCC protein expression in these
cells resulted in suppression of transformed cell properties in vitro
in terms of doubling time, saturation density and anchorage inde-
pendent growth. Induction of apoptosis may have contributed to
this inhibitory action by DCC. It is likely that the different effects
on endometrial carcinoma cells observed in vitro is ascribed to
differences in the level of exogenous DCC cDNA expression.
Thus, prolonged passage of the Ishikawa-derived pDCCCMV-S
transfectants resulted in the appearance of clones in which the
DCC expression level was reduced. These late passage clones did
not exhibit apoptotic cell death under conditions of either 10% or
0.2% serum. The results suggest that a high level of DCC protein
expression that is roughly comparable to that in normal endome-
trial tissues is disadvantageous for DCC-deficient endometrial
cancer cell growth and, as a result, the DCC-expressing cancer
cells are eliminated. The DCC cDNA, under control of the CMV
promoter, transfected into 1811-NMU-TI cells, which had allelic
loss and reduced DCC expression, had little effect on the growth
of cells in culture (Klingelhutz et al, 1995). DCC protein was
detected in these cells; however, the level can not be compared
with that of the cells investigated in the present study.
DCC-negative endometrial carcinoma cells HHUA respond to
introduction of DCC cDNA in suppression of tumour formation in
vivo, though there was little effect on in vitro cell growth except
saturation density. In addition, selective loss of the transcription
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Figure 6 The alteration of DCC expression during the passage. (A) Western blotting of late passaged Ishikawa-derived pDCCCMV transfectant clones.
Parental Ishikawa, 1; early passaged clone 55, 2; late passaged (LP) clone 55, 3; LP clone 519, 4; LP clone 528, 5. In the late passaged clones, band intensity
was significantly reduced, compared with that in early passaged clone 55. (B) RT-PCR with the DCC primer sets were performed and followed by the
hybridization with the radiolabelled DCC probe. Parental Ishikawa, 1; LP clone 519, 2; LP clone 528, 3. Although late passaged clone 519 and 528 did not show
the signal in Western blot, hybridized signal was observed in these cloneswas noticed in tumorigenic revertants. Late-passaged Ishikawa
clones in which the reconstituted expression of DCC was much
lower than early-passaged ones were escaped from apoptosis
induction but still kept the suppressed tumorigenic phenotype. It is
noteworthy that undetectable levels of DCC protein that has abro-
gated a potential to suppress in vitro cell growth or induce apop-
tosis are able to inhibit tumorigenesis of endometrial carcinoma
cells. The previously mentioned 1811-NMU-T1 cells transfected
with full-length DCC cDNA were non-tumorigenic but still
retained the transformed cell properties in vitro. These are compat-
ible with the transfer of a chromosome 18 to endometrial carci-
noma cells. DCC gene transcription in the microcell hybrid under
the control of chromosomal regulatory sequences might be insuffi-
cient to achieve the protein levels detected in normal
endometrium. Thus, the data implicate the outstanding inhibitory
action of DCC protein for tumour formation.
DCC protein is selectively expressed in nerve cells and a small
subset of colonic epithelia (Takagi et al, 1996). In addition, we
demonstrated here that normal human endometrial cells also
expressed high levels of DCC protein. DCC expression is lost
during the progression of tumours originated from these three
types of cells. In turn, much lower levels of DCC protein is
expressed in the normal keratinocytes from which 1181-NMU-T1
cells has been derived (Klingelhutz et al, 1995). A high level of
DCC protein expression results in the inhibition of transformed
cell properties in vitro in endometrial carcinoma cells whereas
little inhibitory effect was shown in 1181-NMU-T1 cells. Thus, it
is possible that carcinoma cells originated from tissues that express
high levels of DCC protein are more sensitive to exogenous DCC
expression.
The present study clearly showed that restoration of DCC
protein expression resulted in the induction of apoptotic cell death
in DCC-deficient endometrial cancer cells. Human endometrium
undergoes morphological and functional alterations in response to
cyclic stimulation of ovarian hormones. Gland epithelium converts
to decidua-like tissues and results in apoptotic cell death in late
secretory phase. DCC induces apoptosis in the absence of ligand
binding, but block apoptosis when engaged by netrin-1 (Mehlen et
al, 1998). Thus, we amplified the netrin-1 cDNAs from normal
endometrial tissues in proliferative and secretory phases to explore
the involvement of netrin-1 and DCC-signalling in cyclic transi-
tion of endometrium. However, we failed to detect netrin-1 expres-
sion in both phases of endometrium. Paracrine secretion of
netrin-1 or other ligand binding would play a role to regulate the
cyclic transition of endometrium. We also failed to amplify netrin-
1 cDNAs from HHUA and Ishikawa endometrial cancer cell lines,
suggesting that netrin-1 expression did not show any relationship
to the differing in vitro expression levels of the transfected DCC
cDNA and its effects.
The functions of DCC associated with tumour suppression
remain to be fully elucidated. DCC shares homology with the
neural cell adhesion molecules and other cell surface molecules of
the immunoglobulin superfamily (Cho et al, 1994) that have been
implicated in a wide variety of processes including differentiation
and metastasis (Takeichi, 1988; Yun et al, 1996). Preferential
localization of DCC protein in a specific subset of differentiated
colon mucosal cells suggests its contribution to intestinal differen-
tiation. However, DCC-deficient mice made by transgene technics
showed no difference in morphological architecture or in differen-
tiation status of intestinal cells compared to normal littermates. In
addition, there was no evidence of increased colon cancer predis-
position in the mice in which one DCC allele was knocked out
(Fazel et al, 1997). These data may suggest that DCC is not
involved in gastrointestinal cell development or carcinogenesis.
But transgenic study does not always reflect a native function of a
gene in human tissues or involvement of a gene in cancer develop-
ment. It is generally accepted that carcinogenesis undergoes multi-
step gene alterations and is influenced by genetic background of
individuals. Considering these with the report that colorectal
cancers with the absent DCC expression have significantly poor
prognosis (Shibata et al, 1996), possible importance of DCC in
colorectal carcinogenesis or cellular differentiation is still implied.
It should be clarified by further investigations and discussed
carefully.
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